key: cord-0702834-pb3150mo
authors: Li, Hong; Gleason, Kevin J.; Hu, Yiran; Lovell, Sandra S.; Mukhopadhyay, Saurabh; Wang, Li; Huang, Bidan
title: Handling death as an Intercurrent event in time to recovery analysis in COVID-19 treatment clinical trials
date: 2022-04-06
journal: Contemp Clin Trials
DOI: 10.1016/j.cct.2022.106758
sha: 4f6f7e3ea8ab5ff647071af06ef96ebacfbcf557
doc_id: 702834
cord_uid: pb3150mo

In clinical trials with the objective to evaluate the treatment effect on time to recovery, such as investigational trials on therapies for COVID-19 hospitalized patients, the patients may face a mortality risk that competes with the opportunity to recover (e.g., be discharged from the hospital). Therefore, an appropriate analytical strategy to account for death is particularly important due to its potential impact on the estimation of the treatment effect. To address this challenge, we conducted a thorough evaluation and comparison of nine survival analysis methods with different strategies to account for death, including standard survival analysis methods with different censoring strategies and competing risk analysis methods. We report results of a comprehensive simulation study that employed design parameters commonly seen in COVID-19 trials and case studies using reconstructed data from a published COVID-19 clinical trial. Our research results demonstrate that, when there is a moderate to large proportion of patients who died before observing their recovery, competing risk analyses and survival analyses with the strategy to censor death at the maximum follow-up timepoint would be able to better detect a treatment effect on recovery than the standard survival analysis that treat death as a non-informative censoring event. The aim of this research is to raise awareness of the importance of handling death appropriately in the time-to-recovery analysis when planning current and future COVID-19 treatment trials.

With the ongoing pandemic of coronavirus disease 2019 (COVID- 19) , investigating treatments for COVID-19 has remained a major task in drug development. In COVID-19 trials in hospitalized patients, key study objectives typically include investigating whether a treatment helps patients recover more quickly than standard of care, as measured by time to hospital discharge over a short duration (e.g., 28 days after randomization). In this type of trial, hospitalized patients also face a mortality risk competing with the opportunity to recover from the disease and be discharged from hospital. In other words, the event of death prevents the opportunity to observe hospital discharge because a deceased patient would never be able to recover and be discharged. Therefore, the competing risk of death must be properly accounted for in the analysis of recovery-based endpoints.

Failure to appropriately account for death in the analysis could potentially underestimate a real treatment effect (risking an effective drug being withheld from patients) or overestimate the treatment effect (risking an ineffective drug becoming recommended treatment). the recovery-like event, including cumulative incidence function [9] [16] [17] , subdistribution hazard model [18] , and cause-specific hazard model [19] . On the topic of COVID-19 clinical trials, one paper criticized that standard survival analysis methods like K-M methods and Cox PH models may lead to biased estimates and conclusions [11] . Ghosh (2021) [13] compared three competing risk regression approaches with application to COVID-19 survival data. However, no previous research has comprehensively investigated the performance of both parametric and non-parametric survival analysis methods with different censoring strategies versus parametric and non-parametric competing risk analysis approaches in the setting of COVID-19 trials.

Our research examined tests of the treatment effect for a time-to-recovery endpoint using nine survival analysis methods with different censoring schemes and modelling approaches through a simulation study and case studies using reconstructed data from a published clinical trial. Given the rapidly shifting landscape of COVID-19 treatment research, our work will increase awareness of the importance of appropriately handling death in the time-to-recovery analysis for current and future COVID-19 trials. Our research will be particularly helpful to address some key questions during study design and analysis planning, including whether standard survival analysis incorporating an appropriate censoring strategy is acceptable in trials of different settings (e.g., severely ill hospitalized patients vs. less ill patients with lower death rates), how different mortality risks between treatment groups may impact the opportunity of claiming a significant treatment effect on recovery, and how to construct a robust survival analysis in such settings.

recovery-based endpoint as the event of interest, and death as the only competing risk event, although one may extend the competing risk to multiple events. The event of interest, recovery or hospital discharge, may be referenced interchangeably.

In the presence of competing risk of death, the incidence function is formulated as the product of the hazard function of the event of interest and the overall survival. It is worth noting that overall survival represents the probability of patients surviving from both the event of interest (i.e., recovery) and the competing event (i.e., death). Thus, overall survival incorporates the effects of the hazard function of the event of interest and the hazard function of the competing risk. In other words, in our motivating example, overall survival acknowledges that a patient must have remained alive in order to experience recovery.

Standard survival analysis approaches, such as Kaplan-Meier and Cox PH model, generally result in upward bias in the estimation of the incidence function in the presence of competing risk(s) [20] [21] [22] . The problem is that, in standard approaches, overall survival does not account for the contribution of the hazard function from the competing risk and is simply attributed to the hazard function of the event of interest only. Thus, it leads to an upward biased overall survival, which in turn leads to an upward biased . For this reason, careful forethought should be given to employ an appropriate analysis method to analyze event onset in the presence of a competing risk.

default censoring mechanism, patients who died would be censored at the time of death (which, for the Cox PH model, will provide an estimate of the cause-specific hazard ratio as briefly mentioned in Section 2.3). Alternatively, one could modify the censoring rules to account for the potential impact of competing death to the event of recovery such that death takes a sufficiently unfavourable value.

For example, in the ACTT-1 trial [8] , patients who died were censored at the end of the efficacy evaluation period. In our simulations in the next section, all three standard survival analysis methods with both censoring strategies (i.e., non-informatively censoring death at death time, or informatively imputing censoring time to the maximum follow up) are examined in comparison with the competing risk analysis methods.

To evaluate the performance of competing risk survival analysis and standard survival analysis methods with different censoring strategies, a simulation study was conducted using settings from COVID-19 clinical trials so that the findings could be easily generalized to real trials and enlighten planning of robust statistical analyses. Note that the statistics in each of the examined analysis methods are different. Therefore, it is not possible to make a direct comparison of all these methods based on a common effect size or treatment effect estimate. Furthermore, for composite endpoints, certain operating characteristics (like bias) are challenging to compute directly. In this simulation study, the probability of observing a significant treatment effect was used to compare different analysis approaches with different statistics. This criterion is also easily interpretable to the research community since it straightforwardly evaluates which methods best demonstrate treatment efficacy when there is indeed a treatment benefit. Details are further described in Section 3.1, Claim of significance of treatment effects.

Simulation settings and analysis R/SAS packages are described in Supplementary Methods. 

In a typical randomized clinical trial, the primary objective is to test the hypothesis of treatment effect for an experimental treatment compared to control. In this simulation study, we analyzed the endpoint of time-to-recovery (e.g., hospital discharge) with various statistical analysis approaches. We estimated the empirical probability of declaring a "statistically significant" treatment effect, Methods for details), when latent times-to-event for recovery and death were simulated from independent or correlated exponential distributions and independent Weibull distributions. For clarity, we use the term "scenario" to describe the distributional forms within each section and "setting" to refer to a unique combination of the four parameters which vary within the scenario.

J o u r n a l P r e -p r o o f

In the first scenario, latent times-to-event for recovery and death were simulated from independent exponential distributions. The hazards for both events (recovery and death) are constant in both treatment arms. Figure 1 plots the empirical probability of a study declaring a statistically significant treatment effect.

The y-axis is the Pr(Significance) as measured by the proportion of simulations claiming the significant treatment effect with one-sided alpha < 0.025. The x-axis plots the hazard ratio for death, with values ranging from 1 to 1/4. As shown in Figure 1A , when the HR of recovery equals 1 (i.e., no difference between groups to directly improve recovery) and the death rate in the control arm is low (5%; left panel), there is almost no difference between approaches in detecting a treatment effect on recovery, regardless of the magnitude of the treatment effect on mortality (HR of death on the x-axis).

On the other hand, when the HR of recovery equals 1 and the death rate is moderate (15%) to large (25%) ( Figure 1A , middle and right panels), there may be a substantial difference between statistical analysis approaches in Pr(significance) when the treatment effect has the benefit to reduce mortality (HR of death <1). For instance, when the HR of death =1/4 and HR of recovery=1, the difference in Pr(significance) was as large as 18% vs. 2.5% if the death rate was 25% in the control group.

Specifically, the competing risk methods (Methods 4, 5, 6) and standard methods using the maximum time censoring approach (Method 1b, 2b, 3b) have notably larger Pr(significance) (i.e., greater chance to claim treatment efficacy) than the standard methods that censor death at the time of death (Methods 1a, 2a, 3a). Note that, for the composite endpoint that incorporates both recovery and death, a true treatment effect exists when there is a treatment effect on either recovery itself or on death. And thus, only the setting furthest to the left in each panel of Figure 1A (HR of recovery = 1 and HR of death = 1) reflects the null hypothesis of no treatment, and the Pr(significance) at that specific setting

represents Type I error rates.

Journal Pre-proof Pr(significance) for the recovery endpoint when the death rate is low (left panels in Figures 1B and   1C ), with the difference never more than 10 percentage points. However, when the death rate is moderate to large (15% or 25%; middle and right panels of Figures 1B and 1C ), the Pr(significance)

can vary substantially between the analysis approaches. When there is no reduction in mortality under experimental treatment (HR of death = 1 in the middle and right panels of Figures 1B and 1C) , the competing risk methods and the maximum time censoring approaches (Methods 4, 5, 6, 1b, 2b, 3b)

actually have slightly lower Pr(significance) than standard methods treating death as non-informative censoring (Methods 1a, 2a, 3a). This phenomenon occurs because deceased patients are placed into the risk set with an immortal time using the competing risk methods (Methods 4, 5, 6) and the maximum time censoring approaches (Method 1b, 2b, 3b). When there is little to no difference in mortality rates between the treatment groups, the larger risk set in these methods will attenuate hazard estimates, resulting in slower separation in the survival curves and less power to detect treatment difference for these approaches compared to the standard methods censoring death at the time of death. On the other hand, when there is a moderate to large treatment effect in reducing mortality (HR of death < 1), the competing risk methods and maximum timepoint censoring approaches have considerably larger Pr(significance) than the standard methods censoring deaths at the time of death.

In these settings, the smaller number of deceased patients in the treatment group will compensate for the 'inflated' risk set caused by a high death rate. This explains why the competing risk methods and the maximum time censoring approaches have considerably larger Pr(significance) than the standard methods beyond a crossing point in the middle and right panels of Figures 1B and 1C .

The median time-to-recovery in the control group is 8 days in Figure 1 , and 12 days and 16 days in Supplementary Materials Figure S1 . Similar findings were observed across settings.

J o u r n a l P r e -p r o o f Journal Pre-proof

In the second and third scenarios, latent times-to-event for recovery and death were simulated from correlated exponential distributions and independent Weibull distributions, respectively. Largely, similar results to Scenario 1 were observed. Another important observation is that when latent timesto-event for recovery and death were simulated from negatively correlated distributions, the standard methods that censor death at the time of death actually showed deflation in Pr(significance) as the treatment effect on reducing mortality increases in magnitude ( Figure S2 ). This is likely due to violating the assumption of non-informative censoring, since in this setting patients with a propensity to experience early death also have a propensity to experience longer times-to-recovery.

Results for these settings (including when hazards were non-proportional) are presented in Supplementary Results.

Two case studies are presented using time-to-event data reconstructed from the RECOVERY trial comparing dexamethasone with usual care in hospitalized COVID-19 patients [24] . The primary outcome of the trial, 28-day mortality, was significantly lower in the dexamethasone group ( 

For the second case study, we evaluated the 9 statistical analysis approaches in analyzing the time-toremoval of MV among the subset of patients on MV at baseline using repeated samples from the reconstructed data to mimic a small to moderate sized trial setting (see Supplementary Methods for details). Table 2 summarizes for each method the empirical probability of detecting significant treatment effect with one-sided p-value < 0.025 (and the average values of the statistics, which are 

Journal Pre-proof 

Well established survival analysis methods to handle competing risk data.

Incorporating the death effect into consideration for the claim of treatment efficacy on recovery. In this work, the evaluation criteria for both simulations and case studies focused on the probability of (statistical) significance since the distinct statistics of different methods are not directly comparable.

However, probability of significance should not be the sole criteria for selection of an appropriate statistical method, nor should researchers rely on a single analysis in evaluating treatment efficacy.

Our comprehensive evaluation also did not suggest that any one method was superior to the others across all scenarios. Therefore, selection of the appropriate analysis method should consider model with appropriate adjustment of the parameters to reflect the study settings.

The time to recovery (e.g., hospital discharge) with competing death was generated using the latent failure time model [26] . Another algorithm, the cause-hazard driven model [27] , was also considered to generate the simulation data. It was observed that the choice of simulation algorithm would not be impactful to the overall conclusion. Both exponential and Weibull distributions were assumed for time to recovery, death, and censored event. In each simulated trial, 360 patients were randomized in a 1:1 ratio to control or treatment. A total of 10,000 trials were simulated in each combination of settings for median recovery, the hazard ratio of discharge, death rate, and hazard ratio of death (a total of 3x3x3x5=135 settings), as specified above.

The on dexamethasone, respectively) from this trial. Specifically, data were reconstructed by scanning incidence curves published in the main text and supplement from RECOVERY using the J o u r n a l P r e -p r o o f WebPlotDigitizer software portal (https://apps.automeris.io/wpd/) and applying the reconstruction algorithm described by Guyot et al. [32] .

The entire sample size of 6425 subjects were used in the evaluations for the first case study. For the second case study, we reconstructed data from the subset of N=1007 subjects (683 on usual care and 324 on dexamethasone, respectively) that were mechanically ventilated at baseline. In this subgroup, there was estimated to be large treatment effects of dexamethasone in both reducing mortality (rate ratio = 0.64) and accelerating the time-to-successful removal of invasive mechanical ventilation (rate ratio = 1.47). Effects of these magnitudes are likely to be detected in such a large trial, regardless of which statistical analysis approach is used. Therefore, we created 10,000 random samples from the full reconstruction data, each containing 180 dexamethasone subjects and 360 usual care subjects.

Within each sample, the data were analyzed using each of the 9 statistical analysis approaches. This setting is driven by our interest in evaluating the performance of these analysis approaches in a more commonly seen, smaller clinical trial while still maintaining the approximate 2:1 ratio from the original study.

All statistical analyses were implemented using R 3.6.1. Non-parametric tests of CIF were conducted by using the cmprsk R package [33] for the modified log-rank Chi-square test [ 

The Supplementary Results present plots showing the proportion of trials across 10,000

simulations that would detect a statistically significant (one-sided p < 0.025) treatment effect on timeto-recovery, Pr(significance), for each analysis approach for all settings and scenarios not presented in Figure 1 .

Settings for Figure S1 are described in the main text. In the Supplement, we present results when latent times-to-recovery and times-to-death are simulated from independent exponential distributions when the median time-to-recovery in control is 12 or 16 days.

In Scenario 2, latent times-to-event for recovery and death were simulated from correlated exponential distributions using the lcmix package in R [36] , with correlation = −0.5. In this scenario, since the times-to-event are negatively correlated, patients with a propensity to experience early death also have a propensity to experience delayed recovery (i.e., longer time-to-recovery). Figure S2 presents results for this scenario when the median time-to-recovery in control is 8 days.

Results when median time-to-recovery was 12 or 16 days were similar (data not shown).

In Scenario 3, latent times-to-event for recovery and death were simulated from independent Weibull distributions. Latent times-to-death were simulated with Weibull shape=1 (i.e., constant hazard as the exponential distribution). In scenarios 3a and 3b as shown in Figures S3a and S3b , times-to-recovery were simulated with the shape parameters equivalent between treatment arms, with shape=0.8 (decreasing recovery rate over time) and shape=1.25 (increasing recovery rate over time)

for 3a and 3b, respectively. In these scenarios, the hazards for time-to-recovery are not constant in either treatment arm, but they are proportional between treatment arms over time. In scenario 3c as shown in Figure S3c , the shape parameters were allowed to differ between treatment arms for timesto-recovery. Latent times-to-recovery in the control arm were simulated with Weibull shape=1. In the treatment arm, shape and scale parameters were selected for an accelerated failure time distribution such that the hazard of recovery in the treatment arm was similar to the hazard of recovery in control near time zero while the HR of recovery were 1, 1.3 or 1.45 at Day 14. In this scenario, patients in the treatment arm start out with similar probability of achieving recovery as patients in the control arm, with an increasingly greater rate of recovery relative to control over time (when the HR of recovery is 1.3 or 1.45 at Day 14) . All results shown are for when the median time-to-recovery in control is 8 days; results when median time-to-recovery was 12 or 16 days were similar (data not shown).

In each Supplemental Figure, the death rate in the control arm is 5%, 15% and 25% for the first, second and third column, respectively. The hazard ratio of discharge equals 1, 1.3 and 1.45 for the first (A), second (B) and third (C) row, respectively.

COVID-19: developing drugs and biological products for treatment or prevention guidance for industry

Nonparametric estimation from incomplete observations

Asymptotically efficient rank invariant test procedures

Regression models and life tables (with discussion)

Restricted mean life with adjustment for covariates

Predicting the restricted mean event time with the subject's baseline covariates in survival analysis

Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in

China: a retrospective cohort study

Dynamic competing risk modeling COVID-19 in a pandemic scenario, arXiv: Populations and Evolution

Statistical analysis of clinical COVID-19 data: a concise overview of lessons learned, common errors and how to avoid them

Risk factors for in-hospital mortality in laboratory-confirmed COVID-19 patients in the Netherlands: a competing risk survival analysis

Comparison of regression approaches for analyzing survival data in the presence of competing risks

Correlates of inhospital COVID-19 deaths: a competing risks survival time analysis of retrospective mortality data

Competing-risk analysis of coronavirus disease 2019 in-hospital mortality in a northern Italian centre from SMAtteo COvid19 REgistry (SMACORE)

How to handle mortality when investigating length of hospital stay and time to clinical stability

A class of k-sample tests for comparing the cumulative incidence of a competing

The analysis of failure times in the presence of competing risks

Competing risk regression models for epidemiologic data

Tutorial in biostatistics: competing risks and multi-state models

Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications

When do we need competing risks methods for survival analysis in nephrology?

Dexamethasone in hospitalized patients with COVID-19

Addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials E9 (R1)

The analysis of failure times in the presence of competing risks

Simulating competing risks data in survival analysis

A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19

A randomized trial of convalescent plasma in COVID-19 severe pneumonia

Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial

Baricitinib plus remdesivir for hospitalized adults with COVID-19

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

Subdistribution analysis of competing risks

Survival: survival analysis

survRM2: comparing restricted mean survival time

lcmix: Layered and chained mixture models

Results when latent times-to-recovery and times-to-death are simulated from independent Weibull distributions, with a median time-to-recovery in the control arm of 8 days. For both treatment and control, shape=1 for time-to-death. For time-to-recovery in the control arm, shape=1 and scale=11.542. For time-to-recovery in the treatment arm, shape and scale parameters were selected such that the hazard ratio would be 1 near time zero and equal to the specified hazard ratio of recovery at 14 days of follow-up. The parameter values for the treatment arm for time-to-recovery are: A) shape=1, scale=11.542; B) shape=1.036, scale=9.336; C) shape=1.051, scale=8.581.J o u r n a l P r e -p r o o f